PT1749818E - Derivados de fenil-piperidina como inibidores da reabsorção da serotonina - Google Patents

Derivados de fenil-piperidina como inibidores da reabsorção da serotonina Download PDF

Info

Publication number
PT1749818E
PT1749818E PT06016609T PT06016609T PT1749818E PT 1749818 E PT1749818 E PT 1749818E PT 06016609 T PT06016609 T PT 06016609T PT 06016609 T PT06016609 T PT 06016609T PT 1749818 E PT1749818 E PT 1749818E
Authority
PT
Portugal
Prior art keywords
reaboresoring
serotonin
inhibitors
phenyl
piperidine derivatives
Prior art date
Application number
PT06016609T
Other languages
English (en)
Portuguese (pt)
Inventor
Garrick Paul Smith
Benny Bang-Andersen
Thomas Ruhland
Ask Pueschl
Kim Andersen
Einer Knud Moltzen
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8160750&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1749818(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of PT1749818E publication Critical patent/PT1749818E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
PT06016609T 2001-10-04 2002-10-02 Derivados de fenil-piperidina como inibidores da reabsorção da serotonina PT1749818E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200101466 2001-10-04

Publications (1)

Publication Number Publication Date
PT1749818E true PT1749818E (pt) 2009-10-06

Family

ID=8160750

Family Applications (2)

Application Number Title Priority Date Filing Date
PT02800051T PT1436271E (pt) 2001-10-04 2002-10-02 Derivados de fenil-piperazina como inibidores da recaptação da serotonina
PT06016609T PT1749818E (pt) 2001-10-04 2002-10-02 Derivados de fenil-piperidina como inibidores da reabsorção da serotonina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT02800051T PT1436271E (pt) 2001-10-04 2002-10-02 Derivados de fenil-piperazina como inibidores da recaptação da serotonina

Country Status (38)

Country Link
US (10) US7144884B2 (cg-RX-API-DMAC7.html)
EP (2) EP1436271B3 (cg-RX-API-DMAC7.html)
JP (3) JP3896116B2 (cg-RX-API-DMAC7.html)
KR (3) KR100783346B1 (cg-RX-API-DMAC7.html)
CN (1) CN1319958C (cg-RX-API-DMAC7.html)
AR (2) AR036659A1 (cg-RX-API-DMAC7.html)
AT (2) ATE386730T1 (cg-RX-API-DMAC7.html)
AU (2) AU2002333220C1 (cg-RX-API-DMAC7.html)
BE (1) BE2014C036I2 (cg-RX-API-DMAC7.html)
BR (3) BR122012023120B8 (cg-RX-API-DMAC7.html)
CA (1) CA2462110C (cg-RX-API-DMAC7.html)
CO (1) CO5580746A2 (cg-RX-API-DMAC7.html)
CY (3) CY1107924T1 (cg-RX-API-DMAC7.html)
DE (2) DE60225162T3 (cg-RX-API-DMAC7.html)
DK (2) DK1436271T6 (cg-RX-API-DMAC7.html)
EA (2) EA007537B3 (cg-RX-API-DMAC7.html)
EG (1) EG25095A (cg-RX-API-DMAC7.html)
ES (2) ES2298425T7 (cg-RX-API-DMAC7.html)
FR (1) FR14C0033I2 (cg-RX-API-DMAC7.html)
HR (1) HRP20040220A2 (cg-RX-API-DMAC7.html)
HU (3) HU228956B1 (cg-RX-API-DMAC7.html)
IL (1) IL160655A0 (cg-RX-API-DMAC7.html)
IS (2) IS2578B (cg-RX-API-DMAC7.html)
LT (1) LTC1436271I2 (cg-RX-API-DMAC7.html)
LU (1) LU92397I2 (cg-RX-API-DMAC7.html)
ME (1) ME00039B (cg-RX-API-DMAC7.html)
MX (1) MXPA04002959A (cg-RX-API-DMAC7.html)
MY (1) MY140950A (cg-RX-API-DMAC7.html)
NL (1) NL300652I2 (cg-RX-API-DMAC7.html)
NO (3) NO326443B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ531556A (cg-RX-API-DMAC7.html)
PL (2) PL210551B1 (cg-RX-API-DMAC7.html)
PT (2) PT1436271E (cg-RX-API-DMAC7.html)
RS (2) RS52326B (cg-RX-API-DMAC7.html)
SI (1) SI1436271T1 (cg-RX-API-DMAC7.html)
UA (2) UA81749C2 (cg-RX-API-DMAC7.html)
WO (1) WO2003029232A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200401583B (cg-RX-API-DMAC7.html)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
GB0305575D0 (en) * 2003-03-11 2003-04-16 Glaxo Group Ltd Novel compounds
CA2521258C (en) * 2003-04-04 2009-12-01 H. Lundbeck A/S 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors
SI1635828T1 (sl) * 2003-04-04 2008-08-31 Lundbeck & Co As H Derivati 4-(2-feniloksifenil)-piperidina ali-1,2,3,6-tetrahidropiridina kot inhibitorji ponovnega privzema serotonina
BRPI0408647A (pt) * 2003-04-04 2006-03-07 Lundbeck & Co As H composto, composição farmacêutica, uso de um composto, e, método para o tratamento de um distúrbio afetivo
EA009417B1 (ru) * 2003-04-04 2007-12-28 Х. Лундбекк А/С Производные 4-(2-фенилоксифенил)пиперидина или -1,2,3,6-тетрагидропиридина в качестве ингибиторов обратного захвата серотонина
UA81300C2 (en) * 2003-04-04 2007-12-25 Lundbeck & Co As H Derivates of 4-(2-fenilsulfanilfenil)-1,2,3,6-tetrahydropiridin as retarding agents of serotonin recapture
ES2303960T3 (es) 2003-12-23 2008-09-01 H. Lundbeck A/S Derivados de 2-(1h-indolilsulfanil)-bencilamina como isrs.
AR052308A1 (es) 2004-07-16 2007-03-14 Lundbeck & Co As H Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto
DE602006007550D1 (de) * 2005-02-10 2009-08-13 Neurosearch As Alkylsubstituierte homopiperazinderivate und deren verwendung als monoamin neurotransmitter wiederaufnahmeinhibitoren
AR054393A1 (es) * 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de benzo(b)furano y benzo(b)tiofeno, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la reabsorcion de neurotransmisores de amina biogenicos.
US7629473B2 (en) 2005-06-17 2009-12-08 H. Lundbeck A/S 2-(1H-indolylsulfanyl)-aryl amine derivatives
AR054394A1 (es) * 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de 2- (1h-indolilsulfanil)-aril amina
JP2007106746A (ja) * 2005-09-13 2007-04-26 Tosoh Corp 新規アリールホモピペラジン類、またはその塩と製造方法
EA016054B1 (ru) * 2006-06-16 2012-01-30 Х. Лундбекк А/С Кристаллические формы 4-[2-(4-метилфенилсульфанил)фенил] пиперидина с объединенным ингибированием повторного поглощения серотонина и норадреналина для лечения невропатической боли
UA95801C2 (ru) * 2006-06-16 2011-09-12 Х. Луннбек А/С Кристаллические формы 4-[2-(4-метилфенилсульфанил)-фенил]пиперидина с комбинированным ингибированием обратного захвата серотонина и норэпинефрина для лечения невропатической боли
RS51687B (sr) * 2006-06-16 2011-10-31 H. Lundbeck A/S. Kristalni oblici 4-[2-4-(4-metilfenilsulfanil)fenil]piperidina sa kombinovanom inhibicijom reapsorpcije serotonina i norepinefrina za lečenje neuropatskog bola
AR061481A1 (es) 2006-06-16 2008-08-27 Lundbeck & Co As H Compuestos con actividad combinada sobre sert, 5-ht3 y 5-ht1a
JP7179035B2 (ja) * 2006-06-16 2022-11-28 ハー・ルンドベック・アクチエゼルスカベット 認識機能障害（ｃｏｇｎｉｔｉｖｅ ｉｍｐａｉｒｍｅｎｔ）を治療するための、組み合わされたセロトニン再取り込み、５－ＨＴ３および５－ＨＴ１Ａ活性を有する化合物としての１－［２－（２，４－ジメチルフェニルスルファニル）－フェニル］ピペラジン
TW200848411A (en) * 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
TWI405588B (zh) * 2007-03-20 2013-08-21 Lundbeck & Co As H ４-〔２-（４-甲苯基硫基）-苯基〕哌啶之鹽類的液體調配物
WO2008151632A1 (en) 2007-06-15 2008-12-18 H.Lundbeck A/S 4- [2- (4-methylphenylsulfanyl) phenyl] piperidine for the treatment of irritable bowel syndrome (ibs)
TWI432194B (zh) * 2007-03-20 2014-04-01 Lundbeck & Co As H ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
AU2014200364B2 (en) * 2007-11-13 2015-09-17 H. Lundbeck A/S Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity
TW200932225A (en) * 2007-12-14 2009-08-01 Lundbeck & Co As H 4-[2,3-difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine
TW200938194A (en) * 2007-12-14 2009-09-16 Lundbeck & Co As H Therapeutic uses of compounds having affinity to the serotonin transporter, serotonin receptors and noradrenalin transporter
WO2009081259A1 (en) * 2007-12-21 2009-07-02 Pfizer Inc. Phenoxy-pyridyl derivatives
UA98698C2 (en) * 2008-03-03 2012-06-11 Х. Луннбек А/С Phenylsulfanylphenyl-piperidines and process for the preparation thereof
PL2358674T3 (pl) * 2008-11-14 2013-06-28 Theravance Inc Sposób otrzymywania związków 4-[2-(2-fluorofenoksymetylo)fenylo]piperydyny
TW201033181A (en) * 2009-02-17 2010-09-16 Lundbeck & Co As H Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
RS53539B1 (sr) * 2009-04-24 2015-02-27 H. Lundbeck A/S Tečne formulacije soli 1-[2-(2,4-dimetilfenilsulfanil)fenil] piperazina
PL2470166T3 (pl) 2009-08-24 2013-11-29 H Lundbeck As Nowe kompozycje 1-[2-(2,4-dimetylofenylosulfanylo)fenylo]piperazyny
US8846655B2 (en) * 2009-10-30 2014-09-30 Janssen Pharmaceutica, Nv 4-substituted-2-phenoxy-phenylamine delta opioid receptor modulators
US8778949B2 (en) 2010-01-11 2014-07-15 Theravance Biopharma R&D Ip, Llc 1-(2-phenoxymethylphenyl)piperazine compounds
EP2550252B1 (en) * 2010-03-22 2015-05-06 Theravance Biopharma R&D IP, LLC 1-(2-phenoxymethylheteroaryl)piperidine and piperazine compounds
PH12012502153A1 (en) * 2010-04-30 2013-02-04 Takeda Pharmaceuticals Co Enteric tablet
CA2797809A1 (en) 2010-04-30 2011-11-03 Takeda Pharmaceutical Company Limited Enteric tablet
EP2407467A1 (de) 2010-07-14 2012-01-18 Sandoz Ag Kristalline Verbindung von 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol und Milchsäure
TW201212918A (en) 2010-08-23 2012-04-01 Lundbeck & Co As H Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
HUE030883T2 (en) 2011-06-20 2017-06-28 H Lundbeck As Deuterated 1-piperazino-3-phenylindanes for the treatment of schizophrenia
RU2622082C2 (ru) 2011-11-14 2017-06-09 Нестек С.А. Анализы и способы выбора режима лечения пациента с депрессией
CN104011034B (zh) * 2012-01-03 2016-08-17 H.隆德贝克有限公司 用于生产1-[2-(2,4-二甲基-苯基硫烷基)-苯基]-哌嗪的方法
US9499504B2 (en) 2012-09-19 2016-11-22 Sandoz Ag Crystalline form of vortioxetine hydrobromide
PL2931276T3 (pl) 2012-12-13 2018-06-29 H. Lundbeck A/S Kompozycje zawierające wortioksetynę i donepezil
MY172337A (en) * 2013-02-22 2019-11-21 H Lundbeck As Vortioxetine manufacturing process
EP3495347A1 (en) 2013-04-04 2019-06-12 LEK Pharmaceuticals d.d. New process for the synthesis of 1-(2-((2,4-dimethylphenyl)thio)phenyl)piperazine
CN104109135B (zh) * 2013-04-22 2018-10-26 江苏豪森药业集团有限公司 1-[2-(2,4-二甲基苯基硫烷基)-苯基]哌嗪的制备方法
IN2013MU03121A (cg-RX-API-DMAC7.html) 2013-09-30 2015-07-17 Cadila Healthcare Ltd
EP2878596A1 (en) 2013-11-29 2015-06-03 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)lithium intermediates
CN104710345B (zh) * 2013-12-17 2017-09-05 江苏恩华药业股份有限公司 用于制备4‑（2‑（4‑甲基苯基硫基））苯基哌啶的化合物、其制备方法及应用
SG11201604944PA (en) 2013-12-20 2016-07-28 Lundbeck & Co As H Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features
EP2894154A1 (en) * 2014-01-14 2015-07-15 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)aniline intermediates
CN103788019B (zh) * 2014-01-22 2015-10-07 苏州明锐医药科技有限公司 沃替西汀的制备方法
EA029060B1 (ru) 2014-01-31 2018-02-28 Эгиш Дьёдьсердьяр Зрт. Способ получения солей вортиоксетина
EP2930171A1 (en) 2014-04-07 2015-10-14 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2,4-dimethylphenyl)(2-iodophenyl)sulfane intermediate
CN104059030B (zh) * 2014-05-30 2016-05-04 镇江圣安医药有限公司 [(苯硫烷基)-苯基]哌嗪的衍生物及其药物组合物和用途
FR3023320B1 (fr) * 2014-07-03 2017-03-10 Ifp Energies Now Systeme et procede de stockage et de recuperation d'energie par gaz comprime avec stockage de la chaleur au moyen d'un echangeur radial
CZ2014471A3 (cs) * 2014-07-08 2016-01-20 Zentiva, K.S. Způsob přípravy vortioxetinu
US9687484B2 (en) 2014-07-18 2017-06-27 Dipharma Francis S.R.L. Crystalline forms of an antidepressant compound
CN104146953A (zh) * 2014-07-24 2014-11-19 李雪梅 一种氢溴酸沃替西汀注射液
CN104292183B (zh) * 2014-09-29 2016-01-06 杨献美 一种抗抑郁药物沃替西汀的制备方法
WO2016079751A2 (en) 2014-11-17 2016-05-26 Megafine Pharma (P) Ltd. A process for preparation of vortioxetine and polymorphs thereof
ES2634496T3 (es) 2014-11-21 2017-09-28 Dipharma Francis S.R.L. Proceso para la preparación de un antidepresivo y los intermedios del mismo
CN104447622B (zh) * 2014-11-28 2017-01-04 郑州大明药物科技有限公司 氢溴酸沃替西汀β晶型的制备方法
CN104586756A (zh) * 2015-01-05 2015-05-06 万特制药(海南)有限公司 一种含沃替西汀的口服溶液及其制备方法
CZ201531A3 (cs) 2015-01-21 2016-08-03 Zentiva, K.S. Polymerem stabilizované amorfní formy vortioxetinu
CN104610195B (zh) * 2015-01-30 2017-06-27 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
WO2016125190A2 (en) 2015-02-04 2016-08-11 Mylan Laboratories Limited Novel crystalline forms of vortioxetine, premixes, and processes for the preparation thereof
WO2016125191A2 (en) 2015-02-04 2016-08-11 Mylan Laboratories Limited Processes for the preparation of vortioxetine hydrobromide
AU2016224930A1 (en) 2015-02-25 2017-09-07 Lupin Limited Process for the preparation of Vortioxetine
US20180072690A1 (en) 2015-03-26 2018-03-15 Cipla Limited Methods for Making Serotonin Reuptake Inhibitors
CN104829557B (zh) * 2015-04-23 2017-06-27 山东百诺医药股份有限公司 一种新化合物1‑[2‑（2,4‑二甲基苯基硫基）苯基]‑2‑氧哌嗪及其制备方法和在沃替西汀合成中的应用
JO3456B1 (ar) 2015-05-13 2020-07-05 H Lundbeck As فيروتيوكسيتين بيروجلوتامات
CA2992161A1 (en) * 2015-07-17 2017-01-26 Institut Pasteur 5-hydroxytryptamine 1b receptor-stimulating agent for use as a promoter of satellite cells self-renewal and/or differentiation
US20180237386A1 (en) * 2015-08-19 2018-08-23 Amneal Pharmaceuticals Company Gmbh Process For Preparation Of Vortioxetine Hydrobromide
WO2017063771A1 (en) * 2015-10-14 2017-04-20 Institut Pasteur 5-hydroxytryptamine 1b receptor-stimulating agent for the treatment of myocardial infarction
CN105461635B (zh) * 2015-11-18 2018-06-08 乳源瑶族自治县大众药品贸易有限公司 苯基哌嗪衍生物及其使用方法和用途
CN105348204B (zh) * 2015-11-18 2018-09-14 乳源瑶族自治县大众药品贸易有限公司 1-杂环基-2-(杂芳基硫基)苯衍生物及其使用方法和用途
US11013830B2 (en) * 2015-11-20 2021-05-25 Institut Pasteur 5-hydroxytryptamine 1B receptor-stimulating agent for enhancing in vivo engraftment potential
WO2017162536A1 (en) 2016-03-21 2017-09-28 H. Lundbeck A/S Vortioxetine prodrugs
CA3026728A1 (en) 2016-07-01 2018-01-04 H. Lundbeck A/S Vortioxetine dosing regimes for fast onset of antidepressant effect
MX386989B (es) 2016-07-15 2025-03-19 Pasteur Institut Agente estimulador del receptor 5-hidroxitriptamina 1b para reparación de piel y/o cabello.
CA3031458A1 (en) * 2016-07-22 2018-01-25 Jiangsu Nhwaluokang Pharmaceutical Research And Development Co., Ltd. Vortioxetine analogue and use and preparation thereof
US20190224192A1 (en) 2016-08-29 2019-07-25 Cipla Limited Stable Pharmaceutical Composition of Vortioxetine Hydrobromide
CN106349132B (zh) * 2016-08-30 2018-02-02 重庆植恩药业有限公司 沃替西汀中间体杂质及其制备方法和用途
US10519121B2 (en) 2016-12-30 2019-12-31 Apicore Us Llc Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts
CN108409729B (zh) * 2017-02-09 2020-11-24 广东东阳光药业有限公司 苯基八氢-1H-吡啶并[1,2-a]吡嗪衍生物及其用途
CN108409728B (zh) * 2017-02-09 2020-11-24 广东东阳光药业有限公司 苯基八氢-1H-吡啶并[1,2-a]吡嗪衍生物及其用途
US10428033B2 (en) 2017-02-15 2019-10-01 Piramal Enterprises Limited Process for the preparation of vortioxetine and salts thereof
EP3582759A4 (en) 2017-02-17 2021-01-06 Unichem Laboratories Ltd BIOEQUIVALENT PHARMACEUTICAL COMPOSITION OF VORTIOXETINE BROMHYDRATE
WO2018154451A1 (en) * 2017-02-23 2018-08-30 Unichem Laboratories Ltd An improved process for preparation and purification of vortioxetine hydrobromide
MX2019012765A (es) * 2017-04-25 2019-12-05 H Lundbeck As Proceso para la fabricacion de la forma alfa de vortioxetina hbr.
EP3412661A1 (en) 2017-06-08 2018-12-12 Enantia, S.L. Cocrystals of vortioxetine hydrobromide and resorcinol
KR102026337B1 (ko) 2017-07-07 2019-09-27 영진약품 주식회사 1-[2-(2,4-디메틸페닐설파닐)페닐]피페라진의 신규염 및 이의 제조방법
CN107915685A (zh) * 2017-12-11 2018-04-17 重庆植恩药业有限公司 一种氢溴酸沃替西汀中间体的制备方法
CN108017595A (zh) * 2017-12-20 2018-05-11 安徽源久源科技有限公司 一种1-[2-(2,5-二甲基苯硫基)苯基]哌嗪的制备方法
EP3810582B1 (en) 2018-06-20 2024-01-03 Vio Ag Pharmaceuticals S.A. A one-pot organo-pseudocatalytic c-h activation approach for the preparation of vortioxetine and vortioxetine intermediate
CN108727393B (zh) * 2018-08-06 2019-10-29 广东东阳光药业有限公司 苯基二氮杂双环衍生物及其用途
CN108863986B (zh) * 2018-08-06 2020-01-21 广东东阳光药业有限公司 二氟甲基取代的苯基哌嗪衍生物及其用途
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
JP2023520016A (ja) 2020-04-03 2023-05-15 ハー・ルンドベック・アクチエゼルスカベット 感情鈍麻の予防又は処置のための１－［２－（２，４－ジメチルフェニルスルファニル）－フェニル］ピペラジン
US12281088B2 (en) 2020-09-10 2025-04-22 Suzhou Fude Zhaofeng Biochemical Technology Co., Ltd Process for the synthesis of vortioxetine
GB2622880A (en) 2022-09-30 2024-04-03 Alkaloid Ad Skopje Palatable orodispersible formulation of vortioxetine
WO2025132869A1 (en) 2023-12-21 2025-06-26 H. Lundbeck A/S Method for the preparation of vortioxetine pharmaceutical compositions with low amounts of nitrosamine impurities
CN120774863A (zh) * 2024-04-02 2025-10-14 王春刚 一种烷基二胺取代双芳杂环基硫醚类化合物及其制备和在制备治疗和/或预防肿瘤药物中的应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS151752B1 (cg-RX-API-DMAC7.html) 1971-04-13 1973-11-19
CS151753B1 (cg-RX-API-DMAC7.html) 1971-04-13 1973-11-19
CS151751B1 (cg-RX-API-DMAC7.html) 1971-04-13 1973-11-19
CS151755B1 (cg-RX-API-DMAC7.html) 1971-04-13 1973-11-19
YU163075A (en) 1975-07-21 1982-05-31 Science Union & Cie Process for preparing new phenoxy derivatives
US4241071A (en) * 1977-01-27 1980-12-23 American Hoechst Corporation Antidepressant (α-phenyl-2-tolyl)azacycloalkanes
US4198417A (en) * 1979-01-10 1980-04-15 American Hoechst Corporation Phenoxyphenylpiperidines
US4198419A (en) * 1979-01-10 1980-04-15 American Hoechst Corporation Phenylthiophenylpiperidines
ES2004809A6 (es) 1987-07-29 1989-02-01 Ferrer Int Procedimiento de obtencion de nuevas 1-(2-(fenilmetil)fenil)piperazinas
GB9126311D0 (en) 1991-12-11 1992-02-12 Wellcome Found Substituted diphenylsulfides
KR100533431B1 (ko) 1995-01-23 2006-05-03 다이이치 아스비오파마 가부시키가이샤 허혈성질환에기인하는증상의완화또는치료용약제및이에유용한화합물
CZ293595A3 (cs) 1995-11-09 1999-12-15 Farmak A. S. Deriváty N,N-dimethyl-2-(arylthio)benzylaminu, jejich soli, způsoby jejich přípravy a jejich použití v léčivých přípravcích
FR2757160B1 (fr) * 1996-12-13 1999-03-12 Sanofi Sa 1-phenylalkyl-1,2,3,6-tetrahydropyridines
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6407099B1 (en) * 1997-10-31 2002-06-18 Suntory Limited Arylpiperidinopropanol and arylpiperazinopropanol derivatives and pharmaceuticals containing the same
EE200100514A (et) 1999-04-02 2002-12-16 Icos Corporation LFA-1 ICAM-idega seondumise inhibiitorid ja nendekasutamine
MXPA02001160A (es) 1999-08-04 2002-07-02 Millennium Pharm Inc Compuestos que se unen a los receptores para melanocortina-4, y metodo de uso de estos.
IL148677A0 (en) * 1999-09-14 2002-09-12 Pharmacopeia Inc Article comprising a multi-channel dispensing head
SK9442002A3 (en) * 1999-12-30 2002-11-06 Lundbeck & Co As H Substituted phenyl-piperazine derivatives, their preparation and use
AU2351701A (en) * 1999-12-30 2001-07-16 H. Lundbeck A/S A method for the preparation of substituted benzene derivatives
US6813639B2 (en) 2000-01-26 2004-11-02 Viaclix, Inc. Method for establishing channel-based internet access network
DE10033548C2 (de) 2000-07-11 2002-05-16 Wolfgang Papenbrock Verfahren zur Vorschau von Internetseiten
US7186715B2 (en) * 2001-01-08 2007-03-06 Eli Lilly And Company Piperazine- and piperidine-derivatives as melanocortin receptor agonists
EP1363890A4 (en) 2001-02-07 2009-06-10 Ore Pharmaceuticals Inc MELANOCORTIN-4-RECEPTOR BINDING COMPOUNDS AND METHOD FOR THEIR APPLICATION
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
EP1458689B1 (en) * 2001-12-20 2007-04-11 H. Lundbeck A/S Aryloxyphenyl and arylsulfanylphenyl derivatives
AR043633A1 (es) 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
CA2521258C (en) * 2003-04-04 2009-12-01 H. Lundbeck A/S 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
AR061481A1 (es) * 2006-06-16 2008-08-27 Lundbeck & Co As H Compuestos con actividad combinada sobre sert, 5-ht3 y 5-ht1a

Also Published As

Publication number Publication date
US7138407B2 (en) 2006-11-21
NO2014011I1 (no) 2014-05-13
BRPI0212733B8 (pt) 2021-05-25
NO332355B1 (no) 2012-09-03
NL300652I1 (cg-RX-API-DMAC7.html) 2016-01-18
EP1749818A3 (en) 2008-04-02
CY2014022I2 (el) 2015-12-09
HU230189B1 (hu) 2015-09-28
AU2006215994B2 (en) 2008-11-13
US7148238B2 (en) 2006-12-12
EP1436271B3 (en) 2022-04-20
ES2298425T7 (es) 2022-06-27
IS7164A (is) 2004-02-26
US7683053B2 (en) 2010-03-23
CN1319958C (zh) 2007-06-06
CO5580746A2 (es) 2005-11-30
EA007537B1 (ru) 2006-10-27
JP2007051149A (ja) 2007-03-01
KR100770194B1 (ko) 2007-10-25
FR14C0033I1 (cg-RX-API-DMAC7.html) 2014-06-13
DE60225162T2 (de) 2009-02-12
EP1749818B1 (en) 2009-09-02
HU228956B1 (en) 2013-07-29
NL300652I2 (cg-RX-API-DMAC7.html) 2016-01-18
AR066460A2 (es) 2009-08-19
KR20040047886A (ko) 2004-06-05
JP3896116B2 (ja) 2007-03-22
US20160137620A1 (en) 2016-05-19
US20120302553A1 (en) 2012-11-29
US20060089368A1 (en) 2006-04-27
US20070060574A1 (en) 2007-03-15
US10844029B2 (en) 2020-11-24
RS20120158A3 (en) 2013-10-31
AU2002333220C1 (en) 2023-10-05
MY140950A (en) 2010-02-12
CA2462110C (en) 2010-05-11
PL210551B1 (pl) 2012-02-29
AU2006215994A2 (en) 2006-10-05
CA2462110A1 (en) 2003-04-10
ME00039B (me) 2010-06-10
BR122012009534C8 (pt) 2021-05-25
DE60225162T3 (de) 2022-08-11
LTPA2014013I1 (lt) 2014-04-25
WO2003029232A1 (en) 2003-04-10
CA2462110E (en) 2003-04-10
NO326443B1 (no) 2008-12-08
MEP6508A (xx) 2010-02-10
CN1561336A (zh) 2005-01-05
AU2002333220B2 (en) 2008-02-07
US20110009423A1 (en) 2011-01-13
US20140163043A1 (en) 2014-06-12
IS8806A (is) 2009-03-10
NZ531556A (en) 2005-12-23
RS52326B (sr) 2012-12-31
DK1436271T6 (da) 2022-06-27
AU2006215994A1 (en) 2006-10-05
EP1436271B1 (en) 2008-02-20
EA007537B3 (ru) 2015-02-27
SI1436271T1 (sl) 2008-06-30
KR20060118020A (ko) 2006-11-17
UA93857C2 (uk) 2011-03-25
CY2014022I1 (el) 2015-12-09
US8476279B2 (en) 2013-07-02
CY1107924T1 (el) 2013-09-04
BR122012009534B1 (pt) 2018-02-27
EA011096B1 (ru) 2008-12-30
UA81749C2 (uk) 2008-02-11
KR100783346B1 (ko) 2007-12-07
ATE441631T1 (de) 2009-09-15
RS27704A (sr) 2006-10-27
PL209253B1 (pl) 2011-08-31
HK1072600A1 (zh) 2005-09-02
PT1436271E (pt) 2008-04-10
US20060084662A1 (en) 2006-04-20
EP1749818A2 (en) 2007-02-07
IL160655A0 (en) 2004-07-25
KR100842702B1 (ko) 2008-07-01
US9090575B2 (en) 2015-07-28
ATE386730T1 (de) 2008-03-15
HUP0402313A3 (en) 2010-03-29
BR0212733A (pt) 2004-11-16
PL368442A1 (pl) 2005-03-21
DK1436271T3 (da) 2008-06-09
JP2007031447A (ja) 2007-02-08
BE2014C036I2 (cg-RX-API-DMAC7.html) 2021-11-22
MXPA04002959A (es) 2004-07-05
US9708280B2 (en) 2017-07-18
RS20120158A2 (sr) 2012-10-31
US20210276966A1 (en) 2021-09-09
US7144884B2 (en) 2006-12-05
NO20083446L (no) 2004-04-21
ES2328725T3 (es) 2009-11-17
HUS1400012I1 (hu) 2020-12-28
JP2005505585A (ja) 2005-02-24
CY1110064T1 (el) 2015-01-14
ES2298425T3 (es) 2008-05-16
EG25095A (en) 2011-08-17
ZA200401583B (en) 2005-05-25
BR122012023120B1 (pt) 2017-03-21
US20050014740A1 (en) 2005-01-20
EA200601269A1 (ru) 2007-02-27
HRP20040220A2 (en) 2005-02-28
AR036659A1 (es) 2004-09-22
IS2578B (is) 2010-02-15
LTC1436271I2 (lt) 2016-09-12
BR0212733B1 (pt) 2014-05-13
KR20070103515A (ko) 2007-10-23
BR122012023120B8 (pt) 2022-01-18
EA200400498A1 (ru) 2004-08-26
EP1436271A1 (en) 2004-07-14
AU2002333220A2 (en) 2003-04-14
RS52865B (sr) 2013-12-31
DE60225162D1 (de) 2008-04-03
IS2732B (is) 2011-04-15
DE60233608D1 (de) 2009-10-15
LU92397I2 (fr) 2014-05-12
US8110567B2 (en) 2012-02-07
JP3955614B2 (ja) 2007-08-08
JP3955613B2 (ja) 2007-08-08
US20180127389A1 (en) 2018-05-10
DK1749818T3 (da) 2009-10-12
AU2006215994A9 (en) 2006-10-05
NO20041628L (no) 2004-04-21
BR122012009534B8 (pt) 2019-01-29
HUP0402313A2 (hu) 2005-02-28
FR14C0033I2 (fr) 2014-11-14
NO2014011I2 (no) 2015-08-31

Similar Documents

Publication Publication Date Title
PT1749818E (pt) Derivados de fenil-piperidina como inibidores da reabsorção da serotonina
AR028576A1 (es) Derivados de b-carbolina utiles como inhibidores de fosfodiesterasa
PT1562902E (pt) Derivados de 2-piridona como inibidores da elastase de neutrofilos
PT1212320E (pt) Fenilpiperazinas como inibidores de reabsorcao de serotonina
AR028575A1 (es) Derivados de pirrolopiridinona utiles como inhibidores de fosfodiesterasa
EE200300478A (et) Tsüklopropüülindooli derivaadid kui selektiivsed serotoniini tagasihaarde inhibiitorid
DK1397364T3 (da) Hidtil ukendte pyrrolderivater som farmaceutiske midler
PT1406628E (pt) Derivados de tera-hidroquinolina
IS8439A (is) Nýjar kínólín afleiður
DK1594840T3 (da) Piperidin-benzensulfonamid-derivater
ATE352550T1 (de) Chinazolinderivate
ATE420066T1 (de) Amidoacetonitrilderivate
ATE395345T1 (de) Imidazol-4-yl-ethynyl-pyridin-derivate
PT1178986E (pt) Derivados da furanona como inibidores da catepsina s
NO20050665L (no) Pyrrolidonderivater som MAOE inhibitoere
IS8180A (is) Nýjar besímídasólafleiður
PT1438289E (pt) Derivados de indole como inibidores de cox ii
MXPA03001848A (es) Derivados de fenoxibencilamina como inhibidores de la reabsorcion de serotonina.
PT1189907E (pt) Tienopirimidinas como inibidores da fosfodiesterase
PT1511718E (pt) Derivados de n-acilaminobenzeno como inibidores selectivos de monoamina-oxidase b
PT1395553E (pt) Derivados de pirrolidina como inibidores do factor xa
IS8364A (is) N-þíasól-2-ýl-bensamíð afleiður
PT1377550E (pt) Derivados eter fenil-heterociclilico como inibidores da recaptacao de serotonina.
DK1706373T3 (da) Amidoacetonitrilderivater
IS8045A (is) Púrín-6-ón-afleiður